NYSE:WSTLife Sciences
West Pharmaceutical Services (WST) Margin Decline Tests Bullish High P E Narrative
West Pharmaceutical Services (WST) has come out of Q1 2026 with investors focused on how its recent quarterly run rate and trailing figures fit together, after the company recorded Q4 2025 revenue of US$805 million, basic EPS of US$1.83 and trailing 12 month EPS of US$6.83 on revenue of about US$3.1 billion. Over the last several quarters, the company has seen revenue move from US$746.9 million in Q3 2024 to US$748.8 million in Q4 2024, then to US$766.5 million in Q2 2025, US$804.6 million in...